• Publications
  • Influence
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
TLDR
Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Erlotinib in previously treated non-small-cell lung cancer.
TLDR
Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
TLDR
To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
TLDR
Despite the fact that the biologic phenotype of ILC is quite favorable, these patients do not have better clinical outcomes than do patients with IDC, and management decisions should be based on individual patient and tumor biologic characteristics.
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
TLDR
IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.
Revision of the American Joint Committee on Cancer staging system for breast cancer.
TLDR
This revised staging system for breast carcinoma will be officially adopted for use in tumor registries in January 2003 and will be useful for the uniform accrual of outcome information in national databases.
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
TLDR
Although available studies suggest that estrogen and progesterone receptors might indeed be helpful in making treatment decisions, their clinical usefulness is still controversial, and there are important unresolved technical issues, such as how to prepare the tissue, which reagents to use and, most importantly, how to interpret the results.
Reporting recommendations for tumor marker prognostic studies (REMARK).
TLDR
These guidelines are designed to encourage transparent and complete reporting of tumor marker studies so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
TLDR
The antitumor activity of tamoxifen in patients with breast cancer may be determined, in part, by tumor levels of AIB1 and HER-2, which may be an important diagnostic and therapeutic target.
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
TLDR
Erlotinib was active and well tolerated in this patient population, and further clinical development is clearly warranted; cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies.
...
...